Find in Library

Colorectal cancer (CRC) is one of the most common cancers and represents a major global health burden. While genetics are implicated in a portion of CRC patients, most cases are sporadic. A new possibility of tumor initiation and promotion might be microbiome composition. It was recently shown that bacteria from the gut microbiome might be used as biomarkers for CRC detection, especially <i>Fusobacterium nucleatum, Peptostreoptococcus stomatis, Parvimonas mica, Solobacterium moorei,</i> and <i>Peptostreptococcus anaerobius.</i> Conversely, the healthy gut microbiome is mostly colonized by Bacterioides (<i>Bacterioides fragilis</i>, <i>vulgatus</i>, <i>uniformis</i>), Firmicutes (<i>Clostridium</i> spp., <i>Ruminococcus faecis</i>, <i>Enterococcus faecium</i>), and Actinobacteria (<i>Bifidobacterium bifidum</i>). Some strains of gut bacteria favor tumor promotion through DNA and RNA damage (directly or through interaction with other known food carcinogens) and through local immune inhibition. It is possible that bacteria (e.g., <i>Bacillus polyfermenticus</i>, <i>Alistipes shahii</i>, <i>Lactobacillus casei</i>) exist with protective functions against tumor promotion. Despite current advances in colorectal cancer treatment, especially in the medical oncology and radiotherapy domains, surgery remains the mainstay of curative treatment for colorectal cancer patients, even in the oligometastatic setting. Surgical complications like anastomotic leakage, excessive blood loss, abscess, and abdominal sepsis can reduce 1-year and 5-year overall survival and increase the recurrence rates for these patients; therefore, we reviewed currently published data focusing on the relationship between gut microbiota and postoperative complications for colorectal cancer patients.